Pancreatic Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

Table Of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 12
2 Introduction 13
2.1 Pancreatic Cancer Diagnostic Tests Overview 13
3 Products under Development 14
3.1 Pancreatic Cancer Diagnostic Tests - Pipeline Products by Stage of Development 14
3.2 Pancreatic Cancer Diagnostic Tests - Pipeline Products by Territory 15
3.3 Pancreatic Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 16
3.4 Pancreatic Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 17
3.5 Pancreatic Cancer Diagnostic Tests - Ongoing Clinical Trials 18
4 Pancreatic Cancer Diagnostic Tests - Pipeline Products under Development by Companies 19
4.1 Pancreatic Cancer Companies - Pipeline Products by Stage of Development 19
4.2 Pancreatic Cancer Diagnostic Tests - Pipeline Products by Stage of Development 22
5 Pancreatic Cancer Diagnostic Tests Companies and Product Overview 25
5.1 A&G Pharmaceutical Inc Company Overview 25
5.1.1 A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 25
5.2 Abcodia Ltd Company Overview 27
5.2.1 Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 27
5.3 Acobiom Company Overview 28
5.3.1 Acobiom Pipeline Products & Ongoing Clinical Trials Overview 28
5.4 Andraka Technologies, LLC Company Overview 30
5.4.1 Andraka Technologies, LLC Pipeline Products & Ongoing Clinical Trials Overview 30
5.5 Applied Proteomics Inc Company Overview 31
5.5.1 Applied Proteomics Inc Pipeline Products & Ongoing Clinical Trials Overview 31
5.6 Asuragen, Inc. Company Overview 32
5.6.1 Asuragen, Inc. Pipeline Products & Ongoing Clinical Trials Overview 32
5.7 Avant Diagnostics, Inc. Company Overview 33
5.7.1 Avant Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 33
5.8 BioMarker Strategies LLC Company Overview 34
5.8.1 BioMarker Strategies LLC Pipeline Products & Ongoing Clinical Trials Overview 34
5.9 Biouniversa srl Company Overview 35
5.9.1 Biouniversa srl Pipeline Products & Ongoing Clinical Trials Overview 35
5.10 Cancer Research Technology Ltd Company Overview 37
5.10.1 Cancer Research Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview 37
5.11 Cepheid Company Overview 38
5.11.1 Cepheid Pipeline Products & Ongoing Clinical Trials Overview 38
5.12 Cleveland Diagnostics Inc. Company Overview 40
5.12.1 Cleveland Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 40
5.13 Clovis Oncology Inc Company Overview 41
5.13.1 Clovis Oncology Inc Pipeline Products & Ongoing Clinical Trials Overview 41
5.14 CompanDX Ltd. Company Overview 43
5.14.1 CompanDX Ltd. Pipeline Products & Ongoing Clinical Trials Overview 43
5.15 Courtagen Life Sciences Inc Company Overview 44
5.15.1 Courtagen Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 44
5.16 CS-Keys, Inc. Company Overview 45
5.16.1 CS-Keys, Inc. Pipeline Products & Ongoing Clinical Trials Overview 45
5.17 Di.V.A.L Toscana srl Company Overview 46
5.17.1 Di.V.A.L Toscana srl Pipeline Products & Ongoing Clinical Trials Overview 46
5.18 Exact Sciences Corp Company Overview 47
5.18.1 Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 47
5.19 German Cancer Research Center Company Overview 49
5.19.1 German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 49
5.20 GlycoZym Company Overview 50
5.20.1 GlycoZym Pipeline Products & Ongoing Clinical Trials Overview 50
5.21 Health Discovery Corp Company Overview 51
5.21.1 Health Discovery Corp Pipeline Products & Ongoing Clinical Trials Overview 51
5.22 Hebrew University of Jerusalem Company Overview 53
5.22.1 Hebrew University of Jerusalem Pipeline Products & Ongoing Clinical Trials Overview 53
5.23 ImmunoCellular Therapeutics Ltd Company Overview 54
5.23.1 ImmunoCellular Therapeutics Ltd Pipeline Products & Ongoing Clinical Trials Overview 54
5.24 Immunomedics Inc Company Overview 56
5.24.1 Immunomedics Inc Pipeline Products & Ongoing Clinical Trials Overview 56
5.25 Immunovia AB Company Overview 58
5.25.1 Immunovia AB Pipeline Products & Ongoing Clinical Trials Overview 58
5.26 Imperial College London Company Overview 62
5.26.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 62
5.27 IV Diagnostics, Inc. Company Overview 63
5.27.1 IV Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 63
5.28 John Hopkins University Company Overview 64
5.28.1 John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 64
5.29 Leitat Technological Center Company Overview 66
5.29.1 Leitat Technological Center Pipeline Products & Ongoing Clinical Trials Overview 66
5.30 Matrix-Bio, Inc. Company Overview 68
5.30.1 Matrix-Bio, Inc. Pipeline Products & Ongoing Clinical Trials Overview 68
5.31 Mayo Clinic US Company Overview 69
5.31.1 Mayo Clinic US Pipeline Products & Ongoing Clinical Trials Overview 69
5.32 MDNA Life Sciences Inc Company Overview 70
5.32.1 MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 70
5.33 Merrimack Pharmaceuticals Inc Company Overview 71
5.33.1 Merrimack Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 71
5.34 Metanomics Health GmbH Company Overview 73
5.34.1 Metanomics Health GmbH Pipeline Products & Ongoing Clinical Trials Overview 73
5.35 Milagen, Inc. Company Overview 74
5.35.1 Milagen, Inc. Pipeline Products & Ongoing Clinical Trials Overview 74
5.36 Miraculins Inc Company Overview 75
5.36.1 Miraculins Inc Pipeline Products & Ongoing Clinical Trials Overview 75
5.37 Myriad Genetics Inc Company Overview 77
5.37.1 Myriad Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview 77
5.38 NanoScale Corporation Company Overview 79
5.38.1 NanoScale Corporation Pipeline Products & Ongoing Clinical Trials Overview 79
5.39 NatiMab Therapeutics Srl Company Overview 80
5.39.1 NatiMab Therapeutics Srl Pipeline Products & Ongoing Clinical Trials Overview 80
5.40 National Cheng-Kung University Hospital Company Overview 81
5.40.1 National Cheng-Kung University Hospital Pipeline Products & Ongoing Clinical Trials Overview 81
5.41 Onconome, Inc. (Inactive) Company Overview 83
5.41.1 Onconome, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 83
5.42 OPKO Health Inc Company Overview 85
5.42.1 OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview 85
5.43 Oxford Gene Technology Ltd Company Overview 87
5.43.1 Oxford Gene Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview 87
5.44 PeriRx LLC Company Overview 88
5.44.1 PeriRx LLC Pipeline Products & Ongoing Clinical Trials Overview 88
5.45 Phenomenome Discoveries Inc Company Overview 89
5.45.1 Phenomenome Discoveries Inc Pipeline Products & Ongoing Clinical Trials Overview 89
5.46 Precision Biologics Inc Company Overview 90
5.46.1 Precision Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview 90
5.47 Proplex Technologies Llc Company Overview 92
5.47.1 Proplex Technologies Llc Pipeline Products & Ongoing Clinical Trials Overview 92
5.48 Protagen AG Company Overview 94
5.48.1 Protagen AG Pipeline Products & Ongoing Clinical Trials Overview 94
5.49 Proteome Sciences Plc Company Overview 95
5.49.1 Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 95
5.50 Queen Mary University of London Company Overview 97
5.50.1 Queen Mary University of London Pipeline Products & Ongoing Clinical Trials Overview 97
5.51 SDIX LLC Company Overview 98
5.51.1 SDIX LLC Pipeline Products & Ongoing Clinical Trials Overview 98
5.52 Sienna Cancer Diagnostics Ltd Company Overview 100
5.52.1 Sienna Cancer Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 100
5.53 SomaLogic Inc Company Overview 101
5.53.1 SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview 101
5.54 Stanford University Company Overview 103
5.54.1 Stanford University Pipeline Products & Ongoing Clinical Trials Overview 103
5.55 Temple University Health System Company Overview 104
5.55.1 Temple University Health System Pipeline Products & Ongoing Clinical Trials Overview 104
5.56 Thomas Jefferson University Company Overview 105
5.56.1 Thomas Jefferson University Pipeline Products & Ongoing Clinical Trials Overview 105
5.57 University of Illinois at Chicago Company Overview 106
5.57.1 University of Illinois at Chicago Pipeline Products & Ongoing Clinical Trials Overview 106
5.58 University of Pennsylvania Company Overview 107
5.58.1 University of Pennsylvania Pipeline Products & Ongoing Clinical Trials Overview 107
5.59 US Biomarkers Inc Company Overview 108
5.59.1 US Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview 108
5.60 Ventana Medical Systems Inc Company Overview 109
5.60.1 Ventana Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 109
5.61 Viomics Inc. Company Overview 110
5.61.1 Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview 110
5.62 Vitatex Inc. Company Overview 111
5.62.1 Vitatex Inc. Pipeline Products & Ongoing Clinical Trials Overview 111
5.63 VolitionRX Ltd Company Overview 113
5.63.1 VolitionRX Ltd Pipeline Products & Ongoing Clinical Trials Overview 113
6 Pancreatic Cancer Diagnostic Tests - Recent Developments 117
6.1 Nov 10, 2016: ImmunoCellular Therapeutics Announces Third Quarter 2016 Financial Results and Provides Research and Development Update 117
6.2 Nov 10, 2016: VolitionRx Announces Third Quarter 2016 Financial Results and Business Update 118
6.3 Nov 09, 2016: Merrimack Reports Third Quarter 2016 Financial Results 119
6.4 Nov 08, 2016: Exact Sciences Appoints Jeff Elliott Chief Financial Officer 121
6.5 Nov 07, 2016: OPKO Health Reports Third Quarter Financial and Operating Results 121
6.6 Nov 07, 2016: Halozyme Reports Third Quarter 2016 Financial Results 122
6.7 Nov 03, 2016: Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update 123
6.8 Nov 02, 2016: Immunomedics Announces First Quarter Fiscal 2017 Results and Clinical Program Developments 125
6.9 Nov 01, 2016: Myriad Genetics Reports Fiscal First-Quarter 2017 Financial Results 126
6.10 Nov 01, 2016: Asuragen Launches QuantideX NGS RNA Lung Cancer Kit 127
6.11 Oct 31, 2016: Proteome Sciences to Raise USD4 Million in Private Placement of Shares 128
6.12 Oct 26, 2016: NeoGenomics Reports 142% Revenue Growth to $60.8 Million and a Record $9.6 Million in Cash Flow from Operations in the Third Quarter of 2016 128
6.13 Oct 21, 2016: Discovery of blood biomarkers for early pancreatic cancer detection 130
6.14 Oct 07, 2016: Upstate receives national designation for pancreatic cancer treatment 130
6.15 Oct 03, 2016: Merrimack Announces Major Corporate Restructuring 131
6.16 Sep 29, 2016: VolitionRX Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 132
6.17 Sep 29, 2016: Myriad Appoints Chip Parkinson as EVP for Reimbursement Strategy 132
6.18 Sep 15, 2016: Immunovia Prices Private Placement of Shares for USD22.3 Million 133
6.19 Sep 15, 2016: Proteome Sciences: Interim Results 133
6.20 Sep 14, 2016: Immunovia Raises USD3.4 Million in Rights Offering of Shares 134
6.21 Sep 13, 2016: OPKO Health Appoints Jane Pine Wood as Chief Legal and Compliance Officer of BioReference Laboratories 134
6.22 Sep 02, 2016: Danaher Acquires Cepheid 134
6.23 Sep 01, 2016: Halozyme Names Mark J. Gergen As Chief Operating Officer 135
6.24 Aug 24, 2016: Immunovia: Half-year report 2016 135
6.25 Aug 23, 2016: BioMarker Strategies Raises USD0.5 Million in Venture Financing 136
6.26 Aug 22, 2016: ImmunoCellular Therapeutics Announces Second Quarter 2016 Financial Results 136
6.27 Aug 17, 2016: Immunomedics Announces Fiscal 2016 Results and Clinical Program Developments 137
6.28 Aug 16, 2016: Immunovia Plans to Raise Funds in Public Offering of Shares 140
6.29 Aug 11, 2016: VolitionRx Announces Second Quarter 2016 Financial Results and Business Update 140
6.30 Aug 09, 2016: ImmunoCellular Therapeutics Prices Public Offering of Shares and Warrants for USD7.5 Million 141
6.31 Aug 09, 2016: Myriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial Results 142
6.32 Aug 09, 2016: Halozyme Reports Second Quarter 2016 Financial Results 143
6.33 Aug 08, 2016: OPKO Health Reports Improved Financial and Operating Results 144
6.34 Aug 08, 2016: Clovis Oncology Announces Q2 2016 Operating Results and Corporate Update 145
6.35 Aug 05, 2016: Sienna Announces Changes To Management Team 147
6.36 Aug 04, 2016: Ambry Genetics Partners with Beth Israel Deaconess Medical Center, University of Pittsburgh and HonorHealth Research Institute 148
6.37 Aug 04, 2016: Merrimack Reports Second Quarter 2016 Financial Results 148
6.38 Jul 28, 2016: Cepheid Reports Second Quarter 2016 Results 149
6.39 Jul 28, 2016: Proteome Sciences: Trading Updateand Notice of Results 150
6.40 Jul 27, 2016: VolitionRx Granted Fourth U.S. Patent 151
6.41 Jul 26, 2016: NeoGenomics Reports 159% Revenue Growth to $63.1 Million and Strong Gains in Profitability in the Second Quarter of 2016 151
6.42 Jul 20, 2016: Protagen Appoints Bernhard Kirschbaum as New Chairman and Oliver Schacht as New Board Member 153
6.43 Jul 15, 2016: Prof. Diane Simeone from University of Michigan Medical Center becomes latest appointment to Immunovia Scientific Advisory Board 153
6.44 Jul 06, 2016: Trovagene Enters into Research Agreement with University of Michigan Comprehensive Cancer Center 154
6.45 Jun 24, 2016: VolitionRx Appoints Dr. Edward Futcher to Board of Directors 154
6.46 Jun 14, 2016: Avant Diagnostics Presented Data on TheraLink Pancreatic Cancer Assay at the International Symposium on Pancreas Cancer 2016 155
6.47 Jun 13, 2016: OPKO Health Announces Move to NASDAQ Stock Market 156
6.48 Jun 09, 2016: Liquid biopsy test - GATCLIQUID ONCOTARGET - expanded to cover blood cancers such as acute myeloid leukaemia 156
6.49 Jun 03, 2016: Thomas Jefferson University and Jefferson Health Recognized By CIO As One Of The CIO 100 Award Winners 157
6.50 Jun 01, 2016: Proteome Sciences Announces CEO Appointment 158
6.51 May 30, 2016: 96 % of early stage pancreatic cancer patients detected in a clinical validation study with a North American sample cohort 159
6.52 May 18, 2016: Proteome Sciences: CEO Appointment 159
6.53 May 18, 2016: Proteome Sciences: Preliminary Results for Year Ended 31st December, 2015 160
6.54 May 13, 2016: VolitionRx Announces First Quarter 2016 Financial Results and Business Update 162
6.55 May 12, 2016: VolitionRx Initiates Clinical Trial with German Cancer Research Center (DKFZ) to Evaluate NuQ Blood Test for Pancreatic Cancer 164
6.56 May 12, 2016: ImmunoCellular Therapeutics Announces First Quarter 2016 Financial Results 165
6.57 May 09, 2016: OPKO Health Reports First Quarter Financial and Operating Results 166
6.58 May 09, 2016: Halozyme Reports First Quarter 2016 Financial Results 167
6.59 Mar 09, 2016: Immunovia partners with leading healthcare consultingservices firm 168
6.60 Mar 09, 2016: Proteome Sciences: Trading update 169
6.61 Feb 29, 2016: Proteome Sciences: Trading Update 169
6.62 Feb 09, 2016: Immunovia Partners with Mount Sinai Health System 170
6.63 Jan 11, 2016: SomaLogic Enters into Agreement with Bristol-Myers Squibb 170
6.64 Dec 03, 2015: IMMray PanCan-d detects 98% of pancreatic cancers in retrospective study with 1400 blood samples 170
7 Appendix 172
7.1 Methodology 172
7.2 About GlobalData 175
7.3 Contact Us 175
7.4 Disclaimer 175

List Of Tables
1.1 List of Tables
Table 1: Pancreatic Cancer Diagnostic Tests - Pipeline Products by Stage of Development 14
Table 2: Pancreatic Cancer Diagnostic Tests - Pipeline Products by Territory 15
Table 3: Pancreatic Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 16
Table 4: Pancreatic Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 17
Table 5: Pancreatic Cancer Diagnostic Tests - Ongoing Clinical Trials 18
Table 6: Pancreatic Cancer Companies - Pipeline Products by Stage of Development 19
Table 7: Pancreatic Cancer Diagnostic Tests - Pipeline Products by Stage of Development 22
Table 8: A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 25
Table 9: Companion Diagnostic Test - Pancreatic Cancer - Product Status 25
Table 10: Companion Diagnostic Test - Pancreatic Cancer - Product Description 26
Table 11: Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 27
Table 12: Diagnostic Assay - Pancreatic Cancer - Product Status 27
Table 13: Diagnostic Assay - Pancreatic Cancer - Product Description 27
Table 14: Acobiom Pipeline Products & Ongoing Clinical Trials Overview 28
Table 15: Companion Diagnostic Assay - Mastinib - Product Status 28
Table 16: Companion Diagnostic Assay - Mastinib - Product Description 29
Table 17: GemciTest - Product Status 29
Table 18: GemciTest - Product Description 29
Table 19: Andraka Technologies, LLC Pipeline Products & Ongoing Clinical Trials Overview 30
Table 20: Diagnostic Test - Pancreatic Cancer - Product Status 30
Table 21: Diagnostic Test - Pancreatic Cancer - Product Description 30
Table 22: Applied Proteomics Inc Pipeline Products & Ongoing Clinical Trials Overview 31
Table 23: API Diagnostic Test - Pancreatic Cancer - Product Status 31
Table 24: API Diagnostic Test - Pancreatic Cancer - Product Description 31
Table 25: Asuragen, Inc. Pipeline Products & Ongoing Clinical Trials Overview 32
Table 26: miRNA Pancreatic Cancer Test - CLIA - Product Status 32
Table 27: miRNA Pancreatic Cancer Test - CLIA - Product Description 32
Table 28: Avant Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 33
Table 29: TheraLink Assay - Pancreatic Cancer - Product Status 33
Table 30: TheraLink Assay - Pancreatic Cancer - Product Description 33
Table 31: BioMarker Strategies LLC Pipeline Products & Ongoing Clinical Trials Overview 34
Table 32: Ex Vivo Biomarker Test - Pancreatic Cancer - Product Status 34
Table 33: Ex Vivo Biomarker Test - Pancreatic Cancer - Product Description 34
Table 34: Biouniversa srl Pipeline Products & Ongoing Clinical Trials Overview 35
Table 35: BAG3 ELISA Kit - Pancreatic Cancer Diagnosis - Product Status 35
Table 36: BAG3 ELISA Kit - Pancreatic Cancer Diagnosis - Product Description 35
Table 37: BAG3 ELISA Kit - Pancreatic Cancer Early Diagnosis - Product Status 36
Table 38: BAG3 ELISA Kit - Pancreatic Cancer Early Diagnosis - Product Description 36
Table 39: Cancer Research Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview 37
Table 40: IHC Based Test - Pancreatic Cancer - Product Status 37
Table 41: IHC Based Test - Pancreatic Cancer - Product Description 37
Table 42: Cepheid Pipeline Products & Ongoing Clinical Trials Overview 38
Table 43: XPERT Pancreatic CA Early Detection Test - Product Status 38
Table 44: XPERT Pancreatic CA Early Detection Test - Product Description 39
Table 45: Xpert Pancreatic CA Monitor Assay - Product Status 39
Table 46: Xpert Pancreatic CA Monitor Assay - Product Description 39
Table 47: Cleveland Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 40
Table 48: Blood-Based Diagnostic Test - Pancreatic Cancer - Product Status 40
Table 49: Blood-Based Diagnostic Test - Pancreatic Cancer - Product Description 40
Table 50: Clovis Oncology Inc Pipeline Products & Ongoing Clinical Trials Overview 41
Table 51: hENT1 Companion Diagnostic Test - Product Status 41
Table 52: hENT1 Companion Diagnostic Test - Product Description 42
Table 53: CompanDX Ltd. Pipeline Products & Ongoing Clinical Trials Overview 43
Table 54: Biomarker Assay - Pancreatic Cancer - Product Status 43
Table 55: Biomarker Assay - Pancreatic Cancer - Product Description 43
Table 56: Courtagen Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 44
Table 57: Pancreatic Cancer Diagnostic Panel - Product Status 44
Table 58: Pancreatic Cancer Diagnostic Panel - Product Description 44
Table 59: CS-Keys, Inc. Pipeline Products & Ongoing Clinical Trials Overview 45
Table 60: caPCNA - Pancreatic Cancer - Product Status 45
Table 61: caPCNA - Pancreatic Cancer - Product Description 45
Table 62: Di.V.A.L Toscana srl Pipeline Products & Ongoing Clinical Trials Overview 46
Table 63: NanoMabKv - Pancreatic Cancer - Product Status 46
Table 64: NanoMabKv - Pancreatic Cancer - Product Description 46
Table 65: Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 47
Table 66: Diagnostic Assay - Pancreatic Cancer - Product Status 47
Table 67: Diagnostic Assay - Pancreatic Cancer - Product Description 48
Table 68: German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 49
Table 69: Diagnostic Assay - Pancreatic Cancer - Product Status 49
Table 70: Diagnostic Assay - Pancreatic Cancer - Product Description 49
Table 71: GlycoZym Pipeline Products & Ongoing Clinical Trials Overview 50
Table 72: Diagnostic Assay - Pancreatic Cancer - Product Status 50
Table 73: Diagnostic Assay - Pancreatic Cancer - Product Description 50
Table 74: Health Discovery Corp Pipeline Products & Ongoing Clinical Trials Overview 51
Table 75: Diagnostic Test - Pancreatic Cancer - Product Status 51
Table 76: Diagnostic Test - Pancreatic Cancer - Product Description 52
Table 77: Hebrew University of Jerusalem Pipeline Products & Ongoing Clinical Trials Overview 53
Table 78: Diagnostic Assay - Pancreatic Cancer - Product Status 53
Table 79: Diagnostic Assay - Pancreatic Cancer - Product Description 53
Table 80: ImmunoCellular Therapeutics Ltd Pipeline Products & Ongoing Clinical Trials Overview 54
Table 81: Diagnostic Test - Pancreatic Cancer - Product Status 54
Table 82: Diagnostic Test - Pancreatic Cancer - Product Description 55
Table 83: Immunomedics Inc Pipeline Products & Ongoing Clinical Trials Overview 56
Table 84: Companion Diagnostic Assay - Clivatuzumab - Product Status 56
Table 85: Companion Diagnostic Assay - Clivatuzumab - Product Description 57
Table 86: Immunovia AB Pipeline Products & Ongoing Clinical Trials Overview 58
Table 87: IMMray PanCan-d - Product Status 58
Table 88: IMMray PanCan-d - Product Description 59
Table 89: IMMray PanCan-m Test - Product Status 59
Table 90: IMMray PanCan-m Test - Product Description 59
Table 91: Immunovia AB - Ongoing Clinical Trials Overview 60
Table 92: IMMray PanCan-d - Validation of Early Detection Blood Test for Pancreatic Cancer 61
Table 93: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 62
Table 94: Prognostic Assay - Pancreatic Cancer - Product Status 62
Table 95: Prognostic Assay - Pancreatic Cancer - Product Description 62
Table 96: IV Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 63
Table 97: Diagnostic Test - Pancreatic Cancer - Product Status 63
Table 98: Diagnostic Test - Pancreatic Cancer - Product Description 63
Table 99: John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 64
Table 100: Antigen Based Diagnostic Assay - Pancreatic Cancer - Product Status 64
Table 101: Antigen Based Diagnostic Assay - Pancreatic Cancer - Product Description 65
Table 102: Protein Biomarker Assay - Pancreatic Cancer - Product Status 65
Table 103: Protein Biomarker Assay - Pancreatic Cancer - Product Description 65
Table 104: Leitat Technological Center Pipeline Products & Ongoing Clinical Trials Overview 66
Table 105: ELISA Kit - S100A4 - Pancreatic Cancer - Product Status 66
Table 106: ELISA Kit - S100A4 - Pancreatic Cancer - Product Description 67
Table 107: ELISA Kit - S100P - Pancreatic Cancer - Product Status 67
Table 108: ELISA Kit - S100P - Pancreatic Cancer - Product Description 67
Table 109: Matrix-Bio, Inc. Pipeline Products & Ongoing Clinical Trials Overview 68
Table 110: VeraMarker Pancreatic Cancer Test - Product Status 68
Table 111: VeraMarker Pancreatic Cancer Test - Product Description 68
Table 112: Mayo Clinic US Pipeline Products & Ongoing Clinical Trials Overview 69
Table 113: Methylation Biomarker Test - Pancreatic Cancer - Product Status 69
Table 114: Methylation Biomarker Test - Pancreatic Cancer - Product Description 69
Table 115: MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 70
Table 116: Diagnostic Assay - Pancreatic Cancer - Product Status 70
Table 117: Diagnostic Assay - Pancreatic Cancer - Product Description 70
Table 118: Merrimack Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 71
Table 119: MM-141 Companion Diagnostic Assay - Pancreatic Cancer - Product Status 71
Table 120: MM-141 Companion Diagnostic Assay - Pancreatic Cancer - Product Description 72
Table 121: Metanomics Health GmbH Pipeline Products & Ongoing Clinical Trials Overview 73
Table 122: Diagnostic Assay - Pancreatic Cancer - Product Status 73
Table 123: Diagnostic Assay - Pancreatic Cancer - Product Description 73
Table 124: Milagen, Inc. Pipeline Products & Ongoing Clinical Trials Overview 74
Table 125: Immunoassay - Pancreatic Cancer - Product Status 74
Table 126: Immunoassay - Pancreatic Cancer - Product Description 74
Table 127: Miraculins Inc Pipeline Products & Ongoing Clinical Trials Overview 75
Table 128: Diagnostic Test - Pancreatic Cancer - Product Status 75
Table 129: Diagnostic Test - Pancreatic Cancer - Product Description 76
Table 130: Myriad Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview 77
Table 131: myPath Pancreatic Cancer - Product Status 77
Table 132: myPath Pancreatic Cancer - Product Description 78
Table 133: NanoScale Corporation Pipeline Products & Ongoing Clinical Trials Overview 79
Table 134: Diagnostic Test - Pancreatic Cancer - Product Status 79
Table 135: Diagnostic Test - Pancreatic Cancer - Product Description 79
Table 136: NatiMab Therapeutics Srl Pipeline Products & Ongoing Clinical Trials Overview 80
Table 137: Diagnostic Test - Pancreas Adenocarcinoma - Product Status 80
Table 138: Diagnostic Test - Pancreas Adenocarcinoma - Product Description 80
Table 139: National Cheng-Kung University Hospital Pipeline Products & Ongoing Clinical Trials Overview 81
Table 140: Diagnostic Biomarker - Pancreatic Cancer - Product Status 81
Table 141: Diagnostic Biomarker - Pancreatic Cancer - Product Description 82
Table 142: Onconome, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 83
Table 143: Pan Cancer Screening and Detection Test - Product Status 83
Table 144: Pan Cancer Screening and Detection Test - Product Description 83
Table 145: Pan-Cancer Metastatic Marker Test - Product Status 84
Table 146: Pan-Cancer Metastatic Marker Test - Product Description 84
Table 147: OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview 85
Table 148: Diagnostic Test - Pancreatic Cancer - Product Status 85
Table 149: Diagnostic Test - Pancreatic Cancer - Product Description 86
Table 150: Oxford Gene Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview 87
Table 151: Diagnostic Test - Pancreatic Cancer - Product Status 87
Table 152: Diagnostic Test - Pancreatic Cancer - Product Description 87
Table 153: PeriRx LLC Pipeline Products & Ongoing Clinical Trials Overview 88
Table 154: Saliva Test - Pancreatic Cancer - Product Status 88
Table 155: Saliva Test - Pancreatic Cancer - Product Description 88
Table 156: Phenomenome Discoveries Inc Pipeline Products & Ongoing Clinical Trials Overview 89
Table 157: PanaSee - Product Status 89
Table 158: PanaSee - Product Description 89
Table 159: Precision Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview 90
Table 160: Diagnostic Assay - Pancreatic Cancer - Product Status 90
Table 161: Diagnostic Assay - Pancreatic Cancer - Product Description 90
Table 162: NEO-301 IHC Test - Product Status 91
Table 163: NEO-301 IHC Test - Product Description 91
Table 164: Proplex Technologies Llc Pipeline Products & Ongoing Clinical Trials Overview 92
Table 165: Biomarker Diagnostic Test - Pancreatic Cancer - Product Status 92
Table 166: Biomarker Diagnostic Test - Pancreatic Cancer - Product Description 93
Table 167: Protagen AG Pipeline Products & Ongoing Clinical Trials Overview 94
Table 168: Diagnostic Assay - Pancreatic Cancer - Product Status 94
Table 169: Diagnostic Assay - Pancreatic Cancer - Product Description 94
Table 170: Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 95
Table 171: SysQuant Global Phosphorylation Assay - Biopsy Tissue - Product Status 95
Table 172: SysQuant Global Phosphorylation Assay - Biopsy Tissue - Product Description 96
Table 173: Queen Mary University of London Pipeline Products & Ongoing Clinical Trials Overview 97
Table 174: Biomarker Assay - Pancreatic Ductal Adenocarcinoma - Product Status 97
Table 175: Biomarker Assay - Pancreatic Ductal Adenocarcinoma - Product Description 97
Table 176: SDIX LLC Pipeline Products & Ongoing Clinical Trials Overview 98
Table 177: Pancreatic Cancer Assay - Product Status 98
Table 178: Pancreatic Cancer Assay - Product Description 99
Table 179: Sienna Cancer Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 100
Table 180: Sienna Test - Pancreatic Cancer - Product Status 100
Table 181: Sienna Test - Pancreatic Cancer - Product Description 100
Table 182: SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview 101
Table 183: SOMAscan Assay - Pancreatic Cancer - Product Status 101
Table 184: SOMAscan Assay - Pancreatic Cancer - Product Description 102
Table 185: Stanford University Pipeline Products & Ongoing Clinical Trials Overview 103
Table 186: Biomarker Assay - Pancreatic Cyst - Product Status 103
Table 187: Biomarker Assay - Pancreatic Cyst - Product Description 103
Table 188: Temple University Health System Pipeline Products & Ongoing Clinical Trials Overview 104
Table 189: Diagnostic Test - Pancreatic Cancer - Product Status 104
Table 190: Diagnostic Test - Pancreatic Cancer - Product Description 104
Table 191: Thomas Jefferson University Pipeline Products & Ongoing Clinical Trials Overview 105
Table 192: Diagnostic Test - Pancreatic Cancer - Product Status 105
Table 193: Diagnostic Test - Pancreatic Cancer - Product Description 105
Table 194: University of Illinois at Chicago Pipeline Products & Ongoing Clinical Trials Overview 106
Table 195: Diagnostic Test - Pancreatic Cancer - Product Status 106
Table 196: Diagnostic Test - Pancreatic Cancer - Product Description 106
Table 197: University of Pennsylvania Pipeline Products & Ongoing Clinical Trials Overview 107
Table 198: Liquid Biopsy Test - Pancreatic Cancer - Product Status 107
Table 199: Liquid Biopsy Test - Pancreatic Cancer - Product Description 107
Table 200: US Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview 108
Table 201: Blood-Based Biomarker - Pancreatic Cancer - Product Status 108
Table 202: Blood-Based Biomarker - Pancreatic Cancer - Product Description 108
Table 203: Ventana Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 109
Table 204: PEGPH20 Companion Diagnostic Assay - Pancreatic Cancer - Product Status 109
Table 205: PEGPH20 Companion Diagnostic Assay - Pancreatic Cancer - Product Description 109
Table 206: Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview 110
Table 207: Viomics Diagnostic Assay - Pancreatic Cancer - Product Status 110
Table 208: Viomics Diagnostic Assay - Pancreatic Cancer - Product Description 110
Table 209: Vitatex Inc. Pipeline Products & Ongoing Clinical Trials Overview 111
Table 210: Pancreatic Cancer CTC Detection Kit - Product Status 111
Table 211: Pancreatic Cancer CTC Detection Kit - Product Description 112
Table 212: VolitionRX Ltd Pipeline Products & Ongoing Clinical Trials Overview 113
Table 213: NuQ Diagnostic Test - Pancreatic Cancer - Product Status 113
Table 214: NuQ Diagnostic Test - Pancreatic Cancer - Product Description 114
Table 215: VolitionRX Ltd - Ongoing Clinical Trials Overview 115
Table 216: NuQ Diagnostic Test - Pancreatic Cancer - Clinical Trial with German Cancer Research Center (DKFZ) to Evaluate NuQ(R) Blood Test for Pancreatic Cancer 116
Table 217: Glossary 173

List Of Figures
1.2 List of Figures
Figure 1: Pancreatic Cancer Diagnostic Tests - Pipeline Products by Stage of Development 14
Figure 2: Pancreatic Cancer Diagnostic Tests - Pipeline Products by Territory 15
Figure 3: Pancreatic Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 16
Figure 4: Pancreatic Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 17
Figure 5: Pancreatic Cancer Diagnostic Tests - Ongoing Clinical Trials 18

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.

Menu 3

Eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.